KR101456994B1 - 안드로겐 수용체 길항제 및 그의 용도 - Google Patents
안드로겐 수용체 길항제 및 그의 용도 Download PDFInfo
- Publication number
- KR101456994B1 KR101456994B1 KR1020127007933A KR20127007933A KR101456994B1 KR 101456994 B1 KR101456994 B1 KR 101456994B1 KR 1020127007933 A KR1020127007933 A KR 1020127007933A KR 20127007933 A KR20127007933 A KR 20127007933A KR 101456994 B1 KR101456994 B1 KR 101456994B1
- Authority
- KR
- South Korea
- Prior art keywords
- delete delete
- compound
- nhr
- group
- certain embodiments
- Prior art date
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/72—Two oxygen atoms, e.g. hydantoin
- C07D233/76—Two oxygen atoms, e.g. hydantoin with substituted hydrocarbon radicals attached to the third ring carbon atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/16—Masculine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/08—Antiseborrheics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/28—Antiandrogens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/86—Oxygen and sulfur atoms, e.g. thiohydantoin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- Dermatology (AREA)
- Diabetes (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US24105109P | 2009-09-10 | 2009-09-10 | |
US61/241,051 | 2009-09-10 | ||
PCT/CN2010/076726 WO2011029392A1 (en) | 2009-09-10 | 2010-09-08 | Androgen receptor antagonists and uses thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20120048705A KR20120048705A (ko) | 2012-05-15 |
KR101456994B1 true KR101456994B1 (ko) | 2014-11-04 |
Family
ID=43732007
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020127007933A KR101456994B1 (ko) | 2009-09-10 | 2010-09-08 | 안드로겐 수용체 길항제 및 그의 용도 |
Country Status (9)
Country | Link |
---|---|
US (2) | US8809550B2 (ja) |
EP (1) | EP2475647B1 (ja) |
JP (1) | JP5659232B2 (ja) |
KR (1) | KR101456994B1 (ja) |
CN (2) | CN102757389B (ja) |
CA (1) | CA2772579C (ja) |
IN (1) | IN2012DN02057A (ja) |
WO (1) | WO2011029392A1 (ja) |
ZA (1) | ZA201202029B (ja) |
Families Citing this family (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103608333B (zh) * | 2011-03-10 | 2016-01-06 | 苏州开拓药业有限公司 | 雄激素受体拮抗剂及其用途 |
CN103159680A (zh) | 2011-12-14 | 2013-06-19 | 爱美尼迪药物有限公司 | 咪唑二酮类化合物及其用途 |
UY34646A (es) | 2012-03-02 | 2013-10-31 | Novartis Ag | Compuestos de espirohidantoína y su uso como moduladores selectivos del receptor de andrógenos |
US9944607B2 (en) | 2012-10-16 | 2018-04-17 | Whitehead Institute For Biomedical Research | Thiohydantoin derivatives and uses thereof |
WO2014078929A1 (pt) * | 2012-11-26 | 2014-05-30 | Universidade Federal De Minas Gerais - Ufmg | Formulações tópicas para a prevenção e tratamento da alopecia e para inibição do crescimento de pêlos |
CN103304439B (zh) * | 2013-06-04 | 2015-08-12 | 常州大学 | 一种4-氨基-2-氟-n-甲基苯甲酰胺的制备方法 |
CN104803919A (zh) * | 2014-01-26 | 2015-07-29 | 上海医药工业研究院 | 用于制备恩杂鲁胺中间体的方法 |
CN103896847B (zh) * | 2014-04-09 | 2016-01-20 | 沈江 | 一种非甾体类抗雄激素化合物及其制备方法和应用 |
CN103910679B (zh) * | 2014-04-23 | 2016-05-25 | 杭州新博思生物医药有限公司 | 一种恩杂鲁胺的制备方法 |
CN104003939B (zh) * | 2014-06-06 | 2017-07-07 | 山东大学 | 二芳基取代乙内酰硫脲类化合物及其制备方法与应用 |
CA2967195A1 (en) * | 2014-11-10 | 2016-05-19 | Glaxosmithkline Intellectual Property (No.2) Limited | Long acting pharmaceutical compositions for hepatitis c |
EP3108879A1 (en) | 2015-06-25 | 2016-12-28 | Cassiopea S.p.A. | High concentration formulation |
EP3481813A1 (en) * | 2016-07-08 | 2019-05-15 | Janssen Pharmaceutica N.V. | Substituted hydantoin and thiohydantoin derivatives as androgen receptor antagonists |
US20190209469A1 (en) * | 2016-08-20 | 2019-07-11 | Ftf Pharma Private Limited | Pharmaceutical composition comprising an androgen receptor inhibitor |
RU2733950C1 (ru) * | 2017-02-13 | 2020-10-08 | Канпу Биофармасьютикалс, Лтд. | Комбинация для лечения рака предстательной железы, фармацевтическая композиция и способ лечения |
CN109700794B (zh) * | 2017-03-01 | 2021-01-08 | 浙江大学 | 腙结构类型雄激素受体拮抗剂及其应用 |
US11292782B2 (en) | 2018-11-30 | 2022-04-05 | Nuvation Bio Inc. | Diarylhydantoin compounds and methods of use thereof |
US20210323931A1 (en) * | 2020-04-17 | 2021-10-21 | Essa Pharma, Inc. | Solid forms of an n-terminal domain androgen receptor inhibitor and uses thereof |
US20230233690A1 (en) * | 2020-07-10 | 2023-07-27 | The Regents Of The University Of Michigan | Androgen receptor protein degraders |
CN112876391A (zh) * | 2021-01-15 | 2021-06-01 | 山东铂源药业有限公司 | 一种4-异硫氰基-2-(三氟甲基)苯甲腈的合成方法 |
CN113024513A (zh) * | 2021-03-22 | 2021-06-25 | 中国药科大学 | 新型雄激素受体降解剂、制备方法和医药用途 |
CN115109031A (zh) * | 2021-03-23 | 2022-09-27 | 苏州开拓药业股份有限公司 | 雄激素受体拮抗剂的无水多晶型物及其制备方法和用途 |
CN115583898A (zh) * | 2021-07-06 | 2023-01-10 | 苏州开拓药业股份有限公司 | 一种异硫氰酸芳基酯的制备方法 |
CN114014850A (zh) * | 2021-12-17 | 2022-02-08 | 山东汇海医药化工有限公司 | 一种普克鲁胺中间体及其合成方法及由该中间体合成普克鲁胺的方法 |
CN114181155A (zh) * | 2021-12-21 | 2022-03-15 | 上海朝晖药业有限公司 | 碘-恩杂鲁胺及其制备方法及其应用 |
CN115181043B (zh) * | 2022-07-27 | 2024-05-07 | 爱斯特(成都)生物制药股份有限公司 | 一种连续流制备4-异硫氰基-2-(三氟甲基)苯甲腈的方法 |
WO2024088395A1 (zh) * | 2022-10-28 | 2024-05-02 | 南京明德新药研发有限公司 | 桥环类化合物及其在药学上的应用 |
CN115819303A (zh) * | 2022-11-15 | 2023-03-21 | 江苏睿实生物科技有限公司 | 一种化合物3-氟-4-异硫氰基-2-三氟甲基苄腈的制备方法 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20070106969A (ko) * | 2004-09-09 | 2007-11-06 | 추가이 세이야쿠 가부시키가이샤 | 신규 이미다졸리딘 유도체 및 그 용도 |
KR20080014039A (ko) * | 2005-05-13 | 2008-02-13 | 더 리전트 오브 더 유니버시티 오브 캘리포니아 | 디아릴히단토인 화합물 |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2694290B1 (fr) | 1992-07-08 | 1994-09-02 | Roussel Uclaf | Nouvelles phénylimidazolidines éventuellement substituées, leur procédé de préparation, leur application comme médicaments et les compositions pharmaceutiques les renfermant. |
TW521073B (en) * | 1994-01-05 | 2003-02-21 | Hoechst Marion Roussel Inc | New optionally substituted phenylimidazolidines, their preparation process, their use as anti-androgenic agent and the pharmaceutical compositions containing them |
FR2725206B1 (fr) | 1994-09-29 | 1996-12-06 | Roussel Uclaf | Nouvelles imidazolidines substituees par un heterocycle, leur procede et des intermediaires de preparation, leur application comme medicaments et les compositions pharmaceutiques les renfermant |
FR2741342B1 (fr) | 1995-11-22 | 1998-02-06 | Roussel Uclaf | Nouvelles phenylimidazolidines fluorees ou hydroxylees, procede, intermediaires de preparation, application comme medicaments, nouvelle utilisation et compositions pharmaceutiques |
FR2742749B1 (fr) | 1995-12-22 | 1998-02-06 | Roussel Uclaf | Nouvelles phenylimidazolidines comportant notamment un radical nitrooxy ou carbonyloxy, procede et intermediaires de preparation, application comme medicaments, nouvelles utilisations et compositions pharmaceutiques |
US6982265B1 (en) | 1999-05-21 | 2006-01-03 | Bristol Myers Squibb Company | Pyrrolotriazine inhibitors of kinases |
US20060025589A1 (en) * | 2002-10-01 | 2006-02-02 | Jean Binet | 2-Thiohydantoine derivative compounds and use thereof for the treatment of diabetes |
TW200612920A (en) * | 2004-08-03 | 2006-05-01 | Chugai Pharmaceutical Co Ltd | Novel imidazolidine derivatives |
US7709517B2 (en) | 2005-05-13 | 2010-05-04 | The Regents Of The University Of California | Diarylhydantoin compounds |
US7709516B2 (en) | 2005-06-17 | 2010-05-04 | Endorecherche, Inc. | Helix 12 directed non-steroidal antiandrogens |
EP3412290B1 (en) * | 2006-03-27 | 2021-03-03 | The Regents of The University of California | Androgen receptor modulator for the treatment of prostate cancer and androgen receptor-associated diseases |
CN101460467B (zh) * | 2006-03-29 | 2012-09-19 | 加利福尼亚大学董事会 | 二芳基硫代乙内酰脲化合物 |
GB0610765D0 (en) | 2006-05-31 | 2006-07-12 | Proskelia Sas | Imidazolidine derivatives, uses therefor, preparation thereof and compositions comprising such |
WO2008093838A1 (ja) * | 2007-02-01 | 2008-08-07 | Chugai Seiyaku Kabushiki Kaisha | スルファモイル基を有するピリジルイミダゾリジン誘導体、およびその医薬としての使用 |
JP5535925B2 (ja) * | 2007-10-26 | 2014-07-02 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | アンドロゲン受容体調節物質としてのジアリールヒダントイン化合物 |
CN101817787B (zh) * | 2009-02-26 | 2013-07-24 | 童友之 | 抗前列腺癌的雄性激素受体拮抗剂 |
CN201520005U (zh) | 2009-09-14 | 2010-07-07 | 三一重工股份有限公司 | 混凝土搅拌站上的收尘装置及带收尘装置的混凝土搅拌系统 |
-
2010
- 2010-09-08 JP JP2012528220A patent/JP5659232B2/ja active Active
- 2010-09-08 CN CN201210081021.1A patent/CN102757389B/zh active Active
- 2010-09-08 WO PCT/CN2010/076726 patent/WO2011029392A1/en active Application Filing
- 2010-09-08 US US13/395,066 patent/US8809550B2/en active Active
- 2010-09-08 KR KR1020127007933A patent/KR101456994B1/ko active IP Right Grant
- 2010-09-08 EP EP10814994.9A patent/EP2475647B1/en active Active
- 2010-09-08 CN CN201080037746.XA patent/CN102482230B/zh active Active
- 2010-09-08 CA CA2772579A patent/CA2772579C/en active Active
-
2012
- 2012-03-07 IN IN2057DEN2012 patent/IN2012DN02057A/en unknown
- 2012-03-19 ZA ZA2012/02029A patent/ZA201202029B/en unknown
-
2014
- 2014-06-03 US US14/294,156 patent/US20140315957A1/en not_active Abandoned
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20070106969A (ko) * | 2004-09-09 | 2007-11-06 | 추가이 세이야쿠 가부시키가이샤 | 신규 이미다졸리딘 유도체 및 그 용도 |
KR20080014039A (ko) * | 2005-05-13 | 2008-02-13 | 더 리전트 오브 더 유니버시티 오브 캘리포니아 | 디아릴히단토인 화합물 |
Also Published As
Publication number | Publication date |
---|---|
EP2475647A1 (en) | 2012-07-18 |
CN102482230B (zh) | 2016-01-06 |
WO2011029392A1 (en) | 2011-03-17 |
JP5659232B2 (ja) | 2015-01-28 |
JP2013504522A (ja) | 2013-02-07 |
EP2475647A4 (en) | 2013-03-27 |
EP2475647B1 (en) | 2015-11-04 |
CN102757389A (zh) | 2012-10-31 |
CA2772579C (en) | 2015-12-08 |
US20140315957A1 (en) | 2014-10-23 |
CN102482230A (zh) | 2012-05-30 |
ZA201202029B (en) | 2012-11-28 |
KR20120048705A (ko) | 2012-05-15 |
US20120172406A1 (en) | 2012-07-05 |
US8809550B2 (en) | 2014-08-19 |
CN102757389B (zh) | 2015-07-08 |
CA2772579A1 (en) | 2011-03-17 |
IN2012DN02057A (ja) | 2015-08-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR101456994B1 (ko) | 안드로겐 수용체 길항제 및 그의 용도 | |
CA2829322C (en) | Substituted thioimidazolidinone androgen receptor antagonists and uses thereof | |
US10857139B2 (en) | Substituted diazaspiroalkanes as androgen receptor modulators | |
JP6152389B2 (ja) | 抗線維化化合物及びその使用 | |
JP2009545594A (ja) | 改善された効能、安定性および安全性を有する疑似塩基ベンゾ[c]フェナントリジン | |
JP2003515590A (ja) | 癌を処置するためのクルクミンアナログ | |
WO2006074293A2 (en) | Bicyclic dihydropyrimidines as eg5 inhibitors | |
US10544100B2 (en) | Autophagy inhibitors | |
US20190070154A1 (en) | New methods of use for an anti-diarrhea agent | |
US20200071321A1 (en) | Methods and uses of compounds for treating disease | |
CA2511199A1 (en) | Small molecule modulators of hepatocyte growth factor (scatter factor) activity | |
RU2068415C1 (ru) | 5,7-диокси-2-метил-8-/4-(3-окси-1-(1-пропил)пиперидинил/-4н-1-бензопиран-4-он или его стереоизомеры или фармакологически приемлемые кислотно-аддитивные соли и способ их получения |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
AMND | Amendment | ||
E902 | Notification of reason for refusal | ||
AMND | Amendment | ||
E601 | Decision to refuse application | ||
AMND | Amendment | ||
X701 | Decision to grant (after re-examination) | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20171024 Year of fee payment: 4 |
|
FPAY | Annual fee payment |
Payment date: 20190925 Year of fee payment: 6 |